FOCUS - IFPW（专注IFPW）.pdf

FOCUS Vol. 22 No. 20 International Federation of Pharmaceutical Wholesalers October 8, 2015 Pharmaceutical Industry’s Use of MA and In Brief . . . Pricing Power for Growth PHOENIX Group reported its total operating performance (Sources: Two articles: One prepared by Hassan Mazhar and published by (revenue as well as handled volume for service charge), increased h e Market Mogul and the other by Joseph Walker and published by the Wall Street Journal) by 6.7% to €14.3 billion (US$16.1 billion) and earnings before h is year, 2015, has been a record breaking year for interest, taxes, depreciation, and amortization (EBITDA) rose pharmaceutical mergers and acquisitions (MA), with deal value to €218.5 million (US$245.6) for its i rst half ended July 31st. in the i rst half of the year reaching a record high of US$221 billion, Results were driven by an increase in revenue in Germany, more than tripling the value of MA deals in the i rst half of 2014. where the pharmaceutical wholesale market experienced h ree key factors have explained this boom in pharmaceutical strong growth and the group also recorded higher revenues in MA: (1) i rms looking to further specialize their operations; the majority of its foreign markets. (2) the ability to acquire approved blockbuster drugs; and (3) the AmerisourceBergen will acquire PharMEDium requirement of cost cutting. Healthcare Holdings